Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

VERSTOVSEK, SRDAN

One or more keywords matched the following items that are connected to VERSTOVSEK, SRDAN

Item Type	Name
Concept	Primary Myelofibrosis
Academic Article	Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Academic Article	Comorbidities predict worse prognosis in patients with primary myelofibrosis.
Academic Article	JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Academic Article	Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Academic Article	Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
Academic Article	Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient.
Academic Article	Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.
Academic Article	MPN-associated myelofibrosis (MPN-MF).
Academic Article	Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Academic Article	Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Academic Article	Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.
Academic Article	Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Academic Article	What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
Academic Article	Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
Academic Article	Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge.
Academic Article	Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Academic Article	Efficacy of ruxolitinib for myelofibrosis.
Academic Article	New approaches in the treatment of myelofibrosis.
Academic Article	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Academic Article	Advances in the therapy of chronic idiopathic myelofibrosis.
Academic Article	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Academic Article	5-Azacitidine has limited therapeutic activity in myelofibrosis.
Academic Article	The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
Academic Article	Treatment of myelofibrosis in younger patients: to transplant or not?
Academic Article	The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
Academic Article	Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia.
Academic Article	JAK2 inhibitors: A reality? A hope?
Academic Article	Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.
Academic Article	Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis.
Academic Article	Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis.
Academic Article	Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
Academic Article	Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Academic Article	JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Academic Article	Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Academic Article	Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
Academic Article	Emerging drugs for myelofibrosis.
Academic Article	Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Academic Article	Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Academic Article	Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis.
Academic Article	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
Academic Article	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Academic Article	Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems.
Academic Article	Experimental therapy in myelofibrosis with myeloid metaplasia.
Academic Article	Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.
Academic Article	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Academic Article	Bortezomib therapy in myelofibrosis: a phase II clinical trial.
Academic Article	Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Academic Article	Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Academic Article	Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
Academic Article	Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
Academic Article	Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
Academic Article	Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Academic Article	Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Academic Article	Ruxolitinib for the treatment of myelofibrosis.
Academic Article	A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Academic Article	Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Academic Article	Ruxolitinib: the first agent approved for myelofibrosis.
Academic Article	Advances in the management of myelofibrosis.
Academic Article	Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
Academic Article	Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Academic Article	The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
Academic Article	The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.
Academic Article	Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS.
Academic Article	Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial.
Academic Article	Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
Academic Article	Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival.
Academic Article	Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Academic Article	A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Academic Article	Changing myelofibrosis's natural course at last.
Academic Article	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Academic Article	Clinical significance of microcytosis in patients with primary myelofibrosis.
Academic Article	Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Academic Article	Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Academic Article	A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Academic Article	Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Academic Article	TP53 mutation is rare in primary myelofibrosis.
Academic Article	Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis.
Academic Article	Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.
Academic Article	Practical management of patients with myelofibrosis receiving ruxolitinib.
Academic Article	Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Academic Article	Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Academic Article	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Academic Article	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Academic Article	Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.
Academic Article	JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
Academic Article	Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.
Academic Article	Paroxysmal nocturnal hemoglobinuria is not a cause of anemia in patients with myelofibrosis.
Academic Article	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Academic Article	Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
Academic Article	Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Academic Article	Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
Academic Article	Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis.
Academic Article	Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor cells?
Academic Article	Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
Academic Article	Ruxolitinib and survival improvement in patients with myelofibrosis.
Academic Article	A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
Academic Article	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Academic Article	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.
Academic Article	Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Academic Article	Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
Academic Article	Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Academic Article	Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome.
Academic Article	Novel therapies for myelofibrosis.
Academic Article	Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Academic Article	Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.
Academic Article	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Academic Article	Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Academic Article	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
Academic Article	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Academic Article	The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
Academic Article	Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib.
Academic Article	A comprehensive review of pacritinib in myelofibrosis.
Academic Article	Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
Academic Article	Outcomes of Allogeneic Hematopoietic Cell Transplantation in?Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Academic Article	Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.
Academic Article	A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia.
Academic Article	Prognosis of Primary Myelofibrosis in the Genomic Era
Academic Article	Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis
Academic Article	Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Academic Article	Novel insights into myelofibrosis pathophysiology and treatment
Academic Article	Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
Academic Article	A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia
Academic Article	Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
Academic Article	A comprehensive review of pacritinib in myelofibrosis
Academic Article	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis
Academic Article	Novel therapies for myelofibrosis
Academic Article	Myelofibrosis-associated complications
Academic Article	Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis
Academic Article	Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Academic Article	An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis
Academic Article	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Academic Article	Bone marrow fibrosis in myelofibrosis
Academic Article	Long non-coding RNAs in primary myelofibrosis
Academic Article	Overcoming treatment challenges in myelofibrosis and polycythemia vera
Academic Article	JAK inhibitors as therapy for myelofibrosis
Academic Article	Primary myelofibrosis associated glomerulopathy
Academic Article	Ruxolitinib for myelofibrosis
Academic Article	The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Academic Article	Myelofibrosis
Academic Article	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Academic Article	Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
Academic Article	Use of the functional assessment of cancer therapy-anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia
Academic Article	Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers
Academic Article	Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
Academic Article	Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome
Academic Article	Myelofibrosis
Academic Article	A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
Academic Article	Primary autoimmune myelofibrosis
Academic Article	The evolution and clinical relevance of prognostic classification systems in myelofibrosis
Academic Article	Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.
Academic Article	Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Academic Article	Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.
Academic Article	The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
Academic Article	Prognosis of Primary Myelofibrosis in the Genomic Era.
Academic Article	Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Academic Article	Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Academic Article	Ruxolitinib dose management as a key to long-term treatment success.
Academic Article	Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Academic Article	Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.
Academic Article	A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
Academic Article	The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
Academic Article	Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Academic Article	'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
Academic Article	Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Academic Article	Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Academic Article	Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Academic Article	Quality and cost comparison of powered versus manual bone marrow biopsy devices in patients with myelofibrosis.
Academic Article	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Academic Article	Myelofibrosis: an update on drug therapy in 2016.
Academic Article	Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Academic Article	An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Academic Article	Primary autoimmune myelofibrosis: a case report and review of the literature.
Academic Article	A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
Academic Article	Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance.
Academic Article	Investigational Janus kinase inhibitors in development for myelofibrosis.
Academic Article	JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Academic Article	Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Academic Article	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Academic Article	Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
Academic Article	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Academic Article	Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
Academic Article	Immunotherapy based approaches in myelofibrosis.
Academic Article	A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Academic Article	Developmental Therapeutics in Myeloproliferative Neoplasms.
Academic Article	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Academic Article	JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis.
Academic Article	The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
Academic Article	Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Academic Article	Therapy-related myelofibrosis does not appear to exist.
Academic Article	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Academic Article	Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Academic Article	Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Academic Article	Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.
Academic Article	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Academic Article	SOHO State-of-the-Art Update and Next Questions: MPN.
Academic Article	Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
Academic Article	Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.
Academic Article	Management of Myelofibrosis-Related Cytopenias.
Academic Article	Renal complications of primary myelofibrosis.
Academic Article	Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.
Academic Article	A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Academic Article	Myelofibrosis osteoclasts are clonal and functionally impaired.
Academic Article	A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
Academic Article	Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Academic Article	New Concepts of Treatment for Patients with Myelofibrosis.
Academic Article	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
Academic Article	SOHO State of the Art Updates and Next Questions: Myelofibrosis.
Academic Article	Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.
Academic Article	The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Academic Article	Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.
Academic Article	Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.
Academic Article	Novel treatment strategies for myeloproliferative neoplasms.
Academic Article	Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.
Academic Article	Mutational profiling in myelofibrosis: implications for management.
Academic Article	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
Academic Article	Prevalence of pulmonary hypertension in myelofibrosis.
Academic Article	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Academic Article	The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.
Academic Article	Management of myelofibrosis after ruxolitinib failure.
Academic Article	Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States.
Academic Article	Survival following allogeneic transplant in patients with myelofibrosis.
Academic Article	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial.
Academic Article	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.
Academic Article	Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis.
Academic Article	New Therapies in Development for Myelofibrosis.
Academic Article	JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.
Academic Article	ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
Academic Article	Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
Academic Article	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
Academic Article	Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Academic Article	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Academic Article	Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy.
Academic Article	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Academic Article	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
Academic Article	SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
Academic Article	Phase II study of single-agent nivolumab in patients with myelofibrosis.
Academic Article	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.
Academic Article	Paradigm shift: combination BET and JAK inhibition in myelofibrosis.
Academic Article	Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Academic Article	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Academic Article	Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
Academic Article	Higher red blood cell distribution width predicts thrombosis risk in primary and secondary myelofibrosis.
Academic Article	SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
Academic Article	Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100???109/L): Final Analysis of an Open-Label Phase 2 Study.
Academic Article	Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.
Academic Article	Disease Modification in Myelofibrosis: An Elusive Goal?
Academic Article	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Academic Article	Momelotinib reduces transfusion requirements in patients with myelofibrosis.
Academic Article	Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
Academic Article	Improved survival of patients with myelofibrosis in the last decade: Single-center experience.
Academic Article	Managing patients with myelofibrosis and thrombocytopenia.
Academic Article	Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Academic Article	The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
Academic Article	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Academic Article	Defining disease modification in myelofibrosis in the era of targeted therapy.
Academic Article	Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Academic Article	GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes.
Academic Article	Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Academic Article	How early intervention impacts long-term survival in myelofibrosis.
Academic Article	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Academic Article	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
Academic Article	Impact of SF3B1 mutation in myelofibrosis.
Academic Article	Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
Academic Article	Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50???109/L to <100???109/L) at baseline: the final analysis of EXPAND.
Academic Article	Biological drivers of clinical phenotype in myelofibrosis.
Academic Article	Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.
Academic Article	Phase III MANIFEST-2: pelabresib?+ ruxolitinib vs placebo?+ ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Academic Article	Anemia in myelofibrosis: Current and emerging treatment options.
Academic Article	BOREAS: a?global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Academic Article	Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Academic Article	Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Academic Article	How I manage anemia related to myelofibrosis and its treatment regimens.
Academic Article	Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
Academic Article	SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
Academic Article	Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
Academic Article	MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Na?ve Myelofibrosis.
Academic Article	Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Academic Article	Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Academic Article	Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Academic Article	Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Academic Article	Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial.
Academic Article	The role of therapy in the outcome of patients with myelofibrosis.
Academic Article	Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Academic Article	Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments.
Academic Article	Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Academic Article	Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
Academic Article	Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Academic Article	Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis.
Academic Article	Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
Academic Article	Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
Academic Article	Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Academic Article	A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.
Academic Article	Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Academic Article	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
Academic Article	Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Academic Article	Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
Academic Article	Erratum to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

Search Criteria

Primary Myelofibrosis